CD200 as a prognostic factor in acute myeloid leukaemia

Tonks, Alex; Hills, Robert Kerrin; White, P. Bruce; Rosie, B.; Mills, Ken I.; Burnett, Alan Kenneth; Darley, Richard Lawrence

doi:10.1038/sj.leu.2404559

Cited by 171 publications

(153 citation statements)

References 9 publications

Supporting

Mentioning

145

Contrasting

Unclassified

Order By: Relevance

“…On dendritic epi-dermal T cells, CD200R crosslinking inhibited ␣CD3-induced proliferation and cytokine secretion (Rosenblum et al, 2005). Recent findings indicate that CD200 expression is up-regulated on leukaemias (Moreaux et al, 2006;Tonks et al, 2007;McWhirter et al, 2006). In addition, blockade of the interaction between CD200 on leukaemic B cells and CD200R on PBMC was found to inhibit tumour growth in an in vivo model of tumour rejection (Kretz-Rommel et al, 2007).…”

Section: Discussionmentioning

confidence: 99%

The inhibitory CD200R is differentially expressed on human and mouse T and B lymphocytes

Rijkers

Ruiter

Baridi

et al. 2008

Molecular Immunology

116

View full text Add to dashboard Cite

To ensure an adequate response against pathogens and prevent unwanted self-reactivity, immune cells need to functionally express both activating and inhibitory receptors. CD200R is an inhibitory receptor mainly expressed on myeloid cells that down-modulates cellular activation both in vivo and in vitro. Although previously mainly studied as a regulator of myeloid function, we now show that CD200R is differentially expressed on human and mouse T-cell subsets. In both species, CD4 + T cells express higher amounts of CD200R than CD8 + T cells, and memory cells express higher amounts of CD200R than naïve or effector cells. CD200R expression is up-regulated on both CD4 + and CD8 + T cells after stimulation in vitro. Furthermore, we show CD200R expression on human and mouse B cells. In human tonsils, CD200R is differentially expressed on B cells, with high expression on memory cells and plasmablasts. Mice lacking the ligand for CD200R, CD200 −/− mice, do not show abnormal composition of the lymphocyte compartment and have normal B cell responses to antigenic challenge. Although the functional implications remain to be elucidated, the expression of CD200R on lymphocytes suggests a much broader role for CD200R-mediated immune regulation than previously anticipated.

show abstract

Section: Discussionmentioning

confidence: 99%

The inhibitory CD200R is differentially expressed on human and mouse T and B lymphocytes

Rijkers

Ruiter

Baridi

et al. 2008

Molecular Immunology

116

View full text Add to dashboard Cite

show abstract

“…Among the genetic markers that has been previously studied in CN-AML patients are Fms-related tyrosine kinase 3 gene (FLT3) mutations [2][3][4][5], the nucleophosmin gene (NPM1) mutations [6][7][8][9][10][11][12][13][14][15], ERG [16,17] and BAALC [18][19][20][21][22] expression levels. Although studies concerning the prognostic relevance of BAALC [18] and ERG expression [16,17] in adult AML patients with CN AML become fully clear; the studies regarding their expression and prognostic impact in pediatric AML are few and of controversial results.…”

Section: Introductionmentioning

confidence: 99%

The Prognostic Relevance of BAALC and ERG Expression Levels in Cytogenetically Normal Pediatric Acute Myeloid Leukemia

Aref

Khodary

Zeed

et al. 2014

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

Cytogenetic aberrations are important prognostic factors in acute myeloid leukemia (AML). About 45 % of de novo adult AML and 20 % of pediatric AML lack cytogenetic abnormalities, so identification of predictive molecular markers might improve therapy. Mutation status of FLT3, NPM1 genes and gene expression levels of ERG, BAALC have been postulated as possible prognostic markers in pediatric AML with normal karyotype. Pretreatment blood samples from 47 cytogenetically normal AML patients were analysed for BAALC and ERG expression using real time RT-PCR. The patients were dichotomized at BAALC and ERG mean expression into low and high expression based on the median expression as cutoff. BAALC showed high expression in (24/47; 51.1 %) of patients and ERG high expression was detected in (22/ 47; 46.6 %). With follow-up for 1 year, patients with high BAALC and high ERG had inferior EFS (P = 0.001, P = 0.017 respectively), overall survival (P = 0.001, 0.08 respectively), and low rates of induction remission (P = 0.001, P = 0.0017 respectively) as compared to those with low expression. Also there was significant positive association between high expression of BAALC; ERG and FLT-ITD mutations (P = 0.016; P = 0.007 respectively). Multivariable analysis confirmed that high BAALC expression is an independent risk factor for EFS [HR for EFS 1.9(1.04-3.46) P = 0.037]; and OS [HR OS 1.55(1.7-3.36) P = 0.03]. In conclusion: Over expression of BAALC could predict adverse clinical outcome and may define important risk factor in cytogenetically normal pediatric AML.

show abstract

“…Expression of CD200 is an independent prognostic factor for multiple myeloma and acute myeloid leukemia, predicting reduced overall survival of these patients (Moreaux et al, 2006;Tonks et al, 2007). CD200 is the ligand for CD200 receptor (CD200R), which is an immune inhibitory receptor expressed on myeloid and lymphoid cells and is considered an important immunological checkpoint (Wright et al, 2001;Rijkers et al, 2008).…”

Section: Introductionmentioning

confidence: 99%

CD200-CD200R signaling suppresses anti-tumor responses independently of CD200 expression on the tumor

et al. 2011

View full text Add to dashboard Cite

CD200 as a prognostic factor in acute myeloid leukaemia

Cited by 171 publications

References 9 publications

The inhibitory CD200R is differentially expressed on human and mouse T and B lymphocytes

The inhibitory CD200R is differentially expressed on human and mouse T and B lymphocytes

The Prognostic Relevance of BAALC and ERG Expression Levels in Cytogenetically Normal Pediatric Acute Myeloid Leukemia

CD200-CD200R signaling suppresses anti-tumor responses independently of CD200 expression on the tumor

Contact Info

Product

Resources

About